HUMA on Nasdaq

Humacyte, Inc.

American biological products company, incorporated in Delaware.

Price unavailable

Last updated Oct 18, 2026.

Overview

Compare with Aligos Therapeutics, Inc., Outlook Therapeutics, Inc. or Proteon Therapeutics, or pick any stock.

  • TickerHUMA on Nasdaq
  • IndustryBiological Products, (No Diagnostic Substances)
  • HeadquartersDE
  • Incorporated inDE2
  • Business address2525 East North Carolina Highway 54, Durham, Nc 277132
  • Filer categoryNon-accelerated filer, Smaller reporting company2

See how the biggest companies compare on our leaderboards

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2025

-5306.0%Operating margin3
-2003.6%Net margin3
-1313.4%Return on equity3
11.40×Debt to equity3
-$105.9MFree cash flow3

What sells

Revenue by product, business segment and region, as the company reports it to the SEC.

Products and services

Product brought in 68% of the revenue Humacyte, Inc. broke down this way in fiscal 2025.

  1. Product$1.4M368%
  2. Product and Service, Other$649.0K332%
Products and services by year
Products and services20242025
Product$0$1.4M
Product and Service, Other$0$649.0K

Where the money goes

Where each dollar of revenue went, fiscal 2025

  • Cost of revenue12¢$9.7M
  • Research and development88¢$69.3M

Out of $2.0M in revenue.3 The company lost money this year.

Financial statements

Revenue3$2.0M in 2025
0$1.0M$2.0M$3.0M2024: $0$020242025: $2.0M$2.0M2025
Operating income45673-$108.1M in 2025+67% since 2020
-$150.0M-$100.0M-$50.0M02020: -$64.6M-$64.6M20202021: -$81.2M-$81.2M2021+26%2022: -$84.6M-$84.6M2022+4%2023: -$100.0M-$100.0M2023+18%2024: -$114.4M-$114.4M2024+14%2025: -$108.1M-$108.1M2025−5%
Net income45673-$40.8M in 2025−39% since 2020
-$150.0M-$100.0M-$50.0M02020: -$66.5M-$66.5M20202021: -$26.5M-$26.5M2021−60%2022: -$12.0M-$12.0M2022−55%2023: -$110.8M-$110.8M2023+826%2024: -$148.7M-$148.7M2024+34%2025: -$40.8M-$40.8M2025−73%

Every line of the income statement as filed: the last 2 fiscal years, latest first.3

Period ending2025-12-312024-12-31
Revenue$2.0M$0
Cost of goods sold$9.7M$0
Research and development$69.3M$88.6M
General and administrative$31.2M$25.8M
Total operating expenses$110.2M$114.4M
Loss from operations-$108.1M-$114.4M
Interest income$2.6M$4.1M
Change in fair value of Contingent Earnout Liability$59.5M-$33.0M
Interest expense-$11.2M-$9.3M
Change in fair value of derivatives$38.8M$3.9M
Loss on extinguishment of debt-$22.3M$0
Total other expense, net$67.3M-$34.3M
Net loss and comprehensive loss-$40.8M-$148.7M
Net loss per share attributable to common stockholders, basic (in dollars per share)-$0.26-$1.26
Net loss per share attributable to common stockholders, diluted (in dollars per share)-$0.26-$1.26
Weighted-average shares outstanding used in computing net loss per share attributable to common stockholders, basic (in shares)158.2M shares118.5M shares
Weighted-average shares outstanding used in computing net loss per share attributable to common stockholders, diluted (in shares)158.2M shares118.5M shares

Compare Humacyte, Inc. with another company

Leadership

Who has led Humacyte, Inc., and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Rajiv Shukla2020
  2. Laura E. Niklason2021–now

President

  1. Laura E. Niklason2021–now

Chief financial officer

  1. Patrick A. Sturgeon2020
  2. Dale A. Sander2021–now

Chief operating officer

  1. Heather Ledbetter Prichard2021–2025
2025
Board members and other officers (23)

Former names

  • Alpha Healthcare Acquisition Corp.Aug 4, 2020 to Aug 26, 20212

Timeline

  1. Aug 27, 2021New chief executive Laura E. Niklason becomes CEO10
  2. Sep 17, 2020New chief executive Rajiv Shukla becomes CEO11

Filings

397 filings to the SEC since October 2021: 5 annual reports, 15 quarterly reports, 61 major events, 201 insider forms, 24 large holders, 91 other. The latest 20:

  1. Oct 7, 20264 EDGAR
  2. Oct 7, 20264 EDGAR
  3. Sep 28, 20263 EDGAR
  4. Sep 28, 20268-K EDGAR
  5. Sep 28, 20263 EDGAR
  6. Sep 15, 20264 EDGAR
  7. Aug 25, 202625-NSE EDGAR
  8. Aug 21, 20264 EDGAR
  9. Aug 19, 20264 EDGAR
  10. Aug 18, 2026SCHEDULE 13D/A EDGAR
  11. Aug 12, 202610-Q EDGAR
  12. Aug 12, 20268-K EDGAR
  13. Jul 31, 20268-K EDGAR
  14. Jul 28, 2026SCHEDULE 13G/A EDGAR
  15. Jul 13, 2026SCHEDULE 13D/A EDGAR
  16. Jun 22, 2026SCHEDULE 13G EDGAR
  17. Jun 15, 2026SCHEDULE 13D/A EDGAR
  18. Jun 12, 20264 OWNERSHIP DOCUMENT EDGAR
  19. Jun 12, 20264 OWNERSHIP DOCUMENT EDGAR
  20. Jun 12, 20264 OWNERSHIP DOCUMENT EDGAR

The 397 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last three years, summarized. The full record is on SEC EDGAR.

Insider trades and holders

Large holders

Investors who own more than 5% must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively. 24 such filings since October 2021, the latest 10:

  1. Aug 18, 2026SCHEDULE 13D/A
  2. Jul 28, 2026SCHEDULE 13G/A
  3. Jul 13, 2026SCHEDULE 13D/A
  4. Jun 22, 2026SCHEDULE 13G
  5. Jun 15, 2026SCHEDULE 13D/A
  6. Apr 27, 2026SCHEDULE 13D/A
  7. Mar 24, 2026SCHEDULE 13D/A
  8. May 22, 2025SCHEDULE 13D/A
  9. Nov 20, 2024SC 13D/A
  10. Nov 18, 2024SC 13D/A

From Forms 4 and Schedules 13D and 13G filed with the SEC.

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 100. Change is in shares since the quarter before.

FundSharesValueShare of the fundChange
ANTIPODES PARTNERS Ltd10,103,647$7.9M0.1%+4,379,897
Vanguard Capital Management LLC10,107,679$7.9M0.0%+2,949,517
Alyeska Investment Group, L.P.6,022,925$4.7M0.0%New
Davidson Kempner Capital Management LP5,000,000$3.9M0.1%New
BlackRock, Inc.4,839,929$3.8M0.0%−7,477,026
Great Point Partners LLC3,750,000$2.9M0.7%No change
UBS Group AG2,843,493$2.2M0.0%+61,423
Aqr Capital Management LLC2,597,134$2.0M0.0%+672,443
Geode Capital Management, LLC2,185,225$1.7M0.0%−1,472,883
Millennium Management LLC1,909,049$1.5M0.0%+1,800,895
Susquehanna International Group, Llp1,699,243$1.3M0.0%+641,195
Citadel Advisors LLC1,443,376$1.1M0.0%New
Charles Schwab Investment Management Inc1,353,515$1.1M0.0%+62,170
Vanguard Fiduciary Trust Co1,181,276$921.4K0.0%+170,247
LPL Financial LLC1,025,535$800.3K0.0%+161,072
Private Advisor Group, LLC965,091$753.2K0.0%+132,292
State Street Corp842,537$657.5K0.0%−2,201,392
Hbk Investments L P790,000$616.5K0.0%New
Wealth Effects LLC693,920$541.5K0.1%+489,420
Lion Point Capital, LP650,000$507.3K2.4%No change
LuminArx Capital Management LP650,000$507.3K0.3%New
Goldman Sachs Group Inc586,524$457.7K0.0%−90,491
Bank Of America Corp /de/578,592$451.3K0.0%+182,479
Vanguard Portfolio Management LLC568,521$443.4K0.0%−849,304
Woodline Partners LP500,582$390.7K0.0%−1,502,000

13F reports cover disclosed long positions in U.S. stocks only.

Members of Congress who traded it

12 trades disclosed by members of Congress. “Vs S&P since” is the stock’s change since the trade minus the S&P 500’s.

DateMemberTradeAmountVs S&P sinceFiling
May 3, 2024Tommy TubervilleRepublican, SenateSale$1,001 - $15,000+141.0%Report
May 3, 2024Tommy TubervilleRepublican, SenatePartial sale$15,001 - $50,000+141.0%Report
Apr 30, 2024Tommy TubervilleRepublican, SenatePartial sale$50,001 - $100,000+142.5%Report
Mar 21, 2024Tommy TubervilleRepublican, SenateBuy$1,001 - $15,000−135.6%Report
Mar 21, 2024Tommy TubervilleRepublican, SenateBuy$1,001 - $15,000−135.6%Report
Mar 21, 2024Tommy TubervilleRepublican, SenateBuy$15,001 - $50,000−135.6%Report
Feb 12, 2024Tommy TubervilleRepublican, SenateBuy$15,001 - $50,000−142.7%Report
Jan 19, 2024Tommy TubervilleRepublican, SenatePartial sale$1,001 - $15,000+143.5%Report
Jul 25, 2023Tommy TubervilleRepublican, SenateBuy$1,001 - $15,000−154.1%Report
Jul 25, 2023Tommy TubervilleRepublican, SenateBuy$1,001 - $15,000−154.1%Report
Jul 25, 2023Tommy TubervilleRepublican, SenateBuy$1,001 - $15,000−154.1%Report
Mar 30, 2022Tommy TubervilleRepublican, SenateBuy$15,001 - $50,000−162.2%Report

Members report amounts as ranges, not exact figures. Returns are price-only (no dividends).

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35